ICD 10 CM C82.67 | Description & Clinical Information

ICD 10 C82.67 describes a specific type of lymphoma known as cutaneous follicle center lymphoma (CFCL) that is characterized by slow growth and primarily affects the skin, but also involves the spleen, and is identified by the presence of centrocytes, which are small and large cleaved follicle center cells, along with some centroblasts, which are intermediate stage B cells.

Official Description Of C82.67

The ICD 10 CM book defines ICD 10 code C82.67 as:

When To Use C82.67

The diagnosis describes by the ICD 10 CM C82.67 code is Cutaneous Follicle Center Lymphoma, also known as CFCL. This type of cancer is slow-growing and typically diagnosed at an advanced stage due to its lack of early symptoms. Patients with CFCL that has progressed to involve the spleen may experience reddish-brown rash or nodules on the skin, as well as a range of other symptoms.

The most common symptoms of CFCL include an enlarged spleen, back and abdominal discomfort, poor appetite, fatigue, weight loss, fever, night sweats, and anemia. As the disease progresses, blood tests may show decreased white blood cells (leukopenia) and thrombocytes (blood cells involved in clotting) and an increase in lymphocytes.

To diagnose CFCL, healthcare providers typically rely on a combination of the patient’s medical history, a physical examination, and a series of diagnostic procedures. These may include a lymph node biopsy and microscopic analysis of the specimen, as well as various blood and imaging tests. Blood tests such as a complete blood cell (CBC) count, LDH, kidney function tests, and liver function tests may help to identify abnormalities and provide insight into the progression of the disease. Imaging studies like computed tomography (CT) or positron emission tomography (PET) may also be performed to evaluate the extent of malignancy and stage the disease based on lymph node involvement and the number of centroblasts per high-power field.

Treatment for CFCL is dependent on the stage and severity of the disease. Patients with few or no symptoms may not require treatment. In contrast, those who develop symptoms or show signs of progressive disease may be treated with radiation for localized disease or chemotherapy for more advanced stages. Depending on the situation, chemotherapy may involve a single agent or multiple agents. Regular follow-up is recommended for all patients with CFCL, as with all forms of cancer.

In summary, CFCL is a slow-growing cancer that can be difficult to diagnose due to a lack of early symptoms. Prompt diagnosis depends on careful examination and a range of diagnostic procedures, including blood and imaging tests. Treatment options vary depending on the stage and severity of the disease, but with proper management, it is possible to successfully manage CFCL and provide patients with the best possible outcomes.